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Predictably irrational: assaying cognitive 
inﬂ  exibility in mouse models of schizophrenia
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The development of sophisticated, translatable mouse-based assays modeling the behavioral 
manifestations of neuropsychiatric diseases, such as schizophrenia, has lagged the advances in 
molecular and genomic techniques. Our laboratory has made efforts to ﬁ  ll this gap by investing in 
the development of novel assays, including adapting a touchscreen-based method for measuring 
cognitive and executive functions for use in mice. As part of these efforts, a recent study by 
Brigman et al. (2009) investigated the effects of subchronic phencyclidine treatment on mouse 
touchscreen-based pairwise visual discrimination and reversal learning. Here, we summarize 
the results of that study, and place them in the larger context of ongoing efforts to develop 
valid mouse “models” of schizophrenia, with a focus on reversal learning and other measures 
of cognitive ﬂ  exibility. Touchscreen-based systems could provide a tractable platform for fully 
utilizing the mouse to elucidate the pathophysiology of cognitive inﬂ  exibility in schizophrenia 
and other neuropsychiatric disorders.
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INTRODUCTION
The last decade has seen the mouse become one 
of the model species of choice for researchers 
studying brain function and neuropsychiatric 
diseases. This trend has been catalyzed by two 
key scientific advances during this period: the 
emergence of techniques for precisely manip-
ulating the mouse genome, such as gene-tar-
geting (Capecchi, 2005), and the sequencing 
of the human genome (International Human 
Genome Sequencing Consortium, 2004). In 
addition, the mouse lends itself to the appli-
cation of other techniques, both traditional 
(e.g., drug treatments, brain lesions) and 
cutting-edge (e.g., RNA interference, optico-
genetics), for manipulating molecules, neuro-
transmitters and circuits in the brain. As such, 
the mouse-based laboratory is now equipped 
with a potent armamentarium of techniques 
to tackle the study of neuropsychiatric disor-
ders. By joining forces with increasingly pow-
erful techniques for studying human subjects, 
such as genome-wide association studies and 
brain imaging (Harrison and Weinberger, 2005; 
Robbins, 2005; Hariri and Holmes, 2006), the 
hope is that research using mice can allow us to 
make some truly novel insights into the patho-
physiology and treatment of neuropsychiatric 
diseases, including schizophrenia.
Arguably, the development of sophisti-
cated, translatable mouse-based assays for the 
behavioral manifestations of schizophrenia has 
lagged the advances in molecular and genomic 
techniques. Contrary to a commonly voiced 
opinion, we do not believe that this is because 
mice are “not smart enough” to perform com-
plex behavioral, particularly cognitive, assays, 
but rather that an adequate investment of time 
and effort has not been put into adapting and 
validating procedures for the mouse.20 | May  2010 | Volume  4 | Issue  1  www.frontiersin.org
tests. We go on to discuss in greater detail various 
mouse assays for “cognitive ﬂ  exibility”, including 
reversal learning – a type of executive function 
impaired in schizophrenia that we and others have 
highlighted as a  particularly tractable, translatable 
process to measure in rodent models of schizo-
phrenia. We end with some concluding remarks 
on some key questions to be addressed in future 
work.
MODELING MAJOR SYMPTOM CATEGORIES 
OF SCHIZOPHRENIA IN MICE
Schizophrenia is a highly heterogeneous disorder 
of myriad symptoms. The presentation of differ-
ent symptoms and their severity varies consider-
ably across patients. While this complexity cannot 
be fully recapitulated in the mouse, speciﬁ  c symp-
tom categories can be behaviorally modeled in 
mice. A constructive starting point has been to 
demarcate schizophrenia-related phenotypes 
into the clinical categories of positive, negative 
and cognitive/executive symptoms (Arguello and 
Gogos, 2006; Powell and Miyakawa, 2006).
Positive symptoms are so-called because they add 
to the normal behavioral repertoire. While a mouse 
test for hallucinations has not yet been proffered, 
In a collaborative venture with Bussey, Saksida 
and colleagues, our laboratory has made efforts 
to ﬁ  ll this gap by investing in the development of 
novel assays, including adapting a touchscreen-
based method for measuring cognitive and 
executive functions for use in mice (Izquierdo 
et al., 2006), and by validating existing models 
of schizophrenia, such as subchronic phencycli-
dine (PCP) treatment, in the touchscreen system 
and other mouse assays. We have sought to uti-
lize these assays to elucidate mechanisms sub-
serving complex behaviors and disease-related 
behavioral dysfunctions. As part of these efforts, 
we have examined pharmacological models of 
schizophrenia in our tasks, and recently reported 
on the effects of subchronic PCP treatment on 
social behavior and cognition (touchscreen-based 
visual discrimination and reversal learning) in 
non-mutant mice (Brigman et al., 2009). Here, we 
summarize these results and put them in the larger 
context of ongoing efforts in the ﬁ  eld to develop 
valid models of schizophrenia, or at least assays 
for some of the main symptoms of the disease, 
in mice. We begin with a brief overview of how 
the major symptoms of schizophrenia are clini-
cally categorized and assayed by mouse  behavioral 
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Figure 1 | Mouse behavioral assays for the major symptom categories of schizophrenia. Positive symptoms. 
The psychomotor agitation and hyper-responsivity to psychotomimetic drugs found in schizophrenia can be modeled 
in mice by testing locomotor responses in novel and stressful environments (A) and locomotor hyperactivity-inducing 
effects of psychotomimetics, such as NMDAR antagonists (B), respectively. Negative symptoms. Schizophrenia is often 
associated with blunted affect, social withdrawal, and loss of pleasure in normally rewarding activities (anhedonia). 
Social interactions with other mice (C) and decreased preference or motivation to obtain rewarding substances, such 
as sucrose (D), can be assessed as a means to model these negative symptoms. Cognitive/executive symptoms. 
Abnormalities in cognition and executive functions are a prominent feature of schizophrenia and range from deﬁ  cits i
n episodic memory, poor attention and sensorimotor gating, to impaired reversal learning and set-shifting. 
Learning and memory can be tested in mice using, e.g., the reference memory version of the Morris water maze (E), 
while prepulse inhibition of the startle response provides a ready measure of sensorimotor gating (F).
Executive functions
A collection of higher-order mental 
processes that exert control over 
information processing, allowing for 
the ability to control, adapt and direct 
behavior in a manner appropriate to 
current environmental demands. 
These include, but are not limited to, 
attention, working memory, behavioral 
ﬂ  exibility and inhibition, and decision 
making. These processes are mediated 
by a well-conserved neural circuitry, 
including the prefrontal cortex (PFC) 
and interconnected subcortical regions, 
such as the striatum.
Reversal learning
A measure of cognitive ﬂ  exibility 
applicable across species in which 
subjects ﬁ  rst learn a stimulus-reward 
association, then the reward association 
is switched. This ostensibly simple 
process taxes multiple executive 
functions, including attention, working 
memory and response inhibition.
Cognitive ﬂ  exibility
Cognitive ﬂ  exibility is a critical 
executive function that can be broadly 
deﬁ  ned as the ability to adapt behaviors 
in response to changes in the 
environment. The Wisconsin Card 
Sorting Task (WCST) is commonly 
used to test cognitive ﬂ  exibility in 
schizophrenic patients, and analogs 
have been developed for rodents 
(e.g., Birrell and Brown “digging task,” 
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control and direct behavior in a manner appro-
priate to current environmental demands. Across 
species, these processes are mediated by neural 
circuitry including the prefrontal cortex (PFC) 
and interconnected subcortical regions, such as 
the striatum (Goldman-Rakic, 1996; Miller and 
Cohen, 2001; Floresco et  al., 2009). Pathology 
in these circuits is a hallmark of schizophrenia 
(Robbins, 2005; Lewis and Gonzalez-Burgos, 
2006; Tan et al., 2009), and is speciﬁ  cally tied 
to the profound executive deﬁ  cits exhibited by 
schizophrenic patients on measures of cognitive 
ﬂ  exibility described below.
Cognitive ﬂ  exibility is a critical executive func-
tion that can be broadly deﬁ  ned as the ability to 
adapt behaviors in response to changes in the 
environment. The Wisconsin Card Sorting Task 
(WCST; Grant and Berg, 1948) has been one of 
the more commonly employed assays for impaired 
cognitive ﬂ  exibility in schizophrenic patients, and 
analogous versions have been developed for use in 
lower species, including mice (Table 2). In essence, 
these tasks involve the subject selecting between 
stimuli, which vary from one another in more 
than one perceptual dimension (or “set”), and 
being reinforced for choosing a stimulus based 
upon one speciﬁ  c dimension alone, e.g., odor. 
During an “intra-dimensional shift” (IDS), the 
form of the dimension the subject must choose 
is changed by the experimenter, e.g., from cinna-
mon to chocolate odor. In an “extra-dimensional 
shift” (EDS), the correct dimension is changed 
altogether, such that choices must be guided by 
the new dimension (texture) while ignoring the 
previously rewarded dimension.
In a rodent IDS/EDS analog of the WCST, rats 
(Birrell and Brown, 2000) or mice (Colacicco 
et al., 2002; Garner et al., 2006; Bissonette et al., 
2008) dig in sand to make choices based on the 
dimension of texture or smell (Figure 2A). As 
in humans, this task is sensitive to PFC dam-
age in rats (Birrell and Brown, 2000) and mice 
(Bissonette et al., 2008). One potentially salient 
difference with the human procedure is that the 
dimensions are in different sensory modalities 
[note: attempts to date to develop a IDS/EDS task 
using a single (visual) modality have not demon-
strated the formation of an attentional set in the 
mouse (Brigman et al., 2005)].
Reversal learning provides another meas-
ure of cognitive ﬂ  exibility. Subjects ﬁ  rst learn 
a   stimulus-reward association, then the reward 
association is switched. Although reversal learn-
ing has been described as hierarchically less 
complex than set-shifting, it requires ﬂ  exible 
switching between cues within the same percep-
tual dimension or modality, and taxes multiple 
other positive symptoms, such as psychomotor agi-
tation and hyper-responsivity to psychotomimetic 
drugs, can be modeled in mice by testing locomo-
tor responses (particularly under provocative situa-
tions, such as stressful  environments) (Figure 1A), 
and locomotor   hyperactivity-inducing effects of 
  psychostimulants (e.g., amphetamine) and other 
psychotomimetics [e.g., N-methyl-Δ-aspartate 
receptor (NMDAR) antagonists dizocilpine/
MK-801 or PCP; Figure 1B].
Rodent models of schizophrenia have tradition-
ally focused on positive symptoms, and this has 
provided many important mechanistic insights 
and drug leads. However, there has been a growing 
emphasis on studying, modeling and treating the 
negative and cognitive/executive symptoms of the 
disease (Carter et al., 2008). Negative symptoms 
(so-called because they subtract from the nor-
mal behavioral repertoire) include blunted affect, 
social withdrawal and loss of pleasure in normally 
rewarding activities (anhedonia). Various rodent 
assays for social behavior and anhedonia (e.g., 
decreased preference or motivation to obtain 
rewarding substances such as sucrose) have been 
typically used to model other disorders, such as 
anxiety (File and Seth, 2003), autism (Crawley, 
2004) and depression (Strekalova et al., 2004), but 
also lend themselves well to the study of abnor-
malities in these behaviors in models of schizo-
phrenia (Figures 1C,D).
The category of cognitive/executive symptoms 
covers a range of abnormalities: from deﬁ  cits in 
episodic memory to impaired attention and sen-
sorimotor gating. Assays for prepulse inhibition 
and latent inhibition provide ready measures 
of sensorimotor gating and selective attention, 
respectively, that can be applied across species 
(Figure 1F). Both have been widely employed 
as a screen for antipsychotics and a measure of 
schizophrenia-related phenotypes in mutant 
mice (Feldon and Weiner, 1992; Geyer et  al., 
2001). There are also numerous very well-studied 
methods for testing various forms of cognition, 
such as the spatial reference memory version of 
the Morris water maze (Figure 1E). However, 
although impaired episodic memory is one of 
the strongest features of the cognitive proﬁ  le of 
schizophrenia (Ranganath et al., 2008), rodent 
models of this disease have not relied upon such 
measures – perhaps because they do not distin-
guish a model of schizophrenia from other con-
ditions that are also characterized by memory 
deﬁ  cits, e.g., Alzheimer’s disease.
MOUSE ASSAYS FOR COGNITIVE FLEXIBILITY
Executive functions subserve the selection and 
processing of information necessary to plan, 
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comparable to reversal tasks being employed in 
patients (Robbins et al., 1994) and higher species 
(non-human primates), Bussey and colleagues 
established a touchscreen-based operant sys-
tem in which rats and mice learn to discriminate 
and reverse between two visual stimuli projected 
onto a touch-sensitive computer screen (Bussey 
et al., 1994, 2001) (Figure 2E). Demonstrating 
the translatable potential for mapping mouse 
studies onto systems in the human, reversal per-
formance in this system is PFC-dependent, as 
conﬁ  rmed by lesion studies in the rat (Bussey 
et  al., 1997; Chudasama and Robbins, 2003) 
and to some extent in the mouse (Brigman and 
Rothblat, 2008).
In addition to its comparability to human 
measures of reversal, this paradigm has several 
unique beneﬁ  ts (for discussion, see Bussey et al., 
2008). Of note, the automation of the task makes 
it relatively free of experimenter inﬂ  uences that 
can vary across individuals and laboratories, and 
inﬂ  uence results (Crabbe et al., 1999). The  system 
executive functions, including attention, working 
memory and response inhibition (Roberts, 2006). 
In addition, reversal learning paradigms allow 
for a direct measure of perseverative responding 
to a previously rewarded stimuli or cue, as it 
is present, but unrewarded, during the reversal 
phase. This is  particularly pertinent because per-
severation,   possibly caused by insensitivity to 
negative feedback (i.e., non-reward) following 
incorrect responding, is a feature of impaired 
reversal in schizophrenia (Leeson et al., 2009).
TOUCHSCREEN-BASED MEASURE 
OF REVERSAL LEARNING IN MICE
Various tasks have been developed to measure 
reversal in rats and mice in maze (Mackintosh 
et al., 1968; Ragozzino et al., 1999; Stefani et al., 
2003; Floresco et al., 2008) as well as operant 
settings (e.g., Ferry et al., 2000; Schoenbaum 
et al., 2000; Bohn et al., 2003a,b; Schoenbaum 
et al., 2004) (Figures 2B–D). In an effort to pro-
vide a procedure that was more analogous and 
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Figure 2 | Mouse behavioral assays for cognitive ﬂ  exibility. 
(A) Intra-dimensional/extra-dimensional digging task. Mice are trained to dig 
for food reward using either olfactory (digging medium odor) or tactile (digging 
medium texture) cues. The rewarded cue in the same dimension is switched to 
test for intra-dimensional shifting. The rewarded cue is changed to the different 
dimension to test for extra-dimensional shifting. (B) Spatial reversal in Morris 
water maze. After learning to locate a submerged platform using distal spatial 
cues (see Figure 1E), the platform location is moved to the opposite side of the 
pool to test for reversal. (C) Spatial reversal in T-maze. After learning to locate 
a food reward in one goal arm using distal spatial cues, the rewarded goal arm 
is switched to test for reversal. (D) Reversal of discriminated operant response 
in a bar-pressing system. After learning to press a lever for reward based 
on a visual (e.g., light) or spatial (lever location) cue, the rewarded cue is 
switched to test for reversal. (E) Reversal of discriminated operant response in 
a touchscreen-based system. Reversal of a discriminated operant response 
can also be tested using a touchscreen-based system (for details, see Figure 3).
Touchscreen-based operant system
A system in which rats and mice learn 
to discriminate and reverse between 
two visual stimuli projected onto 
a touch-sensitive computer screen. 
It provides a procedure more analogous 
and comparable to reversal tasks 
employed in human subjects. Can be 
readily modiﬁ  ed to test for a battery 
of cognitive and executive functions.Frontiers in Neuroscience  May  2010 | Volume  4 | Issue  1 | 23
were signiﬁ  cantly impaired in chronic hospi-
talized schizophrenic patients with frontal lobe 
damage (Pantelis et  al., 1999). Interestingly, 
more stabilized patients were found to be more 
speciﬁ  cally impaired on reversal and EDS shifts 
(Elliott et al., 1995; Waltz and Gold, 2007) and 
some ﬁ  rst-episode schizophrenics exhibited even 
more restricted, EDS-only, impairment (Hutton 
et al., 1998; Joyce et al., 2002; Braw et al., 2008). 
These ﬁ  ndings raise the interesting possibility 
that the proﬁ  le of discrimination/reversal/set-
shifting impairment may be graded in a manner 
corresponding to the chronicity of schizophre-
nia (Joyce et al., 2002). On the other hand, there 
are clinical data showing clear deﬁ  cits in both 
reversal and set-shifting in ﬁ  rst-episode schizo-
phrenics, and especially in those patients with 
prominent thought disorganization symptoms 
(Barnett et al., 2005; Murray et al., 2008; Leeson 
et al., 2009). One interpretation of these ﬁ  nd-
ings is that the breadth and pattern of deﬁ  cits 
in discrimination/reversal/set-shifting may be 
more of a marker for speciﬁ  c subtypes of the 
disease rather than of disease severity (Leeson 
et al., 2009). The touchscreen procedure could 
prove to be valuable for delineating discrimina-
tion and reversal impairments in mouse models, 
and thereby shed light on the pathophysiology 
underlying their dissociation in different sub-
populations of schizophrenic patients.
EFFECTS OF SUBCHRONIC PCP TREATMENT 
ON DISCRIMINATION AND REVERSAL
There is compelling evidence implicating the 
glutamate system in the pathophysiology of 
schizophrenia (Coyle, 2006). As part of a larger 
is also very ﬂ  exible and can be easily adapted to 
test for other forms of cognition and executive 
function other than discrimination and reversal, 
such as extinction (Hefner et al., 2008), spatial 
paired-associate learning (associating an object 
with a spatial location) (Talpos et al., 2009) and 
pattern separation (discrimination of perceptu-
ally similar stimuli) (Clelland et al., 2009).
In our formulation of the task (Izquierdo 
et  al., 2006; Brigman et  al., 2008) (Figure 3), 
mice are ﬁ  rst trained to initiate the appearance 
of the stimuli on-screen by a head entry into 
a magazine where food pellets are delivered 
(Figure 3A). There is then some training to 
shape the mouse to touch the screen to obtain 
reward before discrimination learning begins 
(Figure 3B). Discrimination is typically between 
two (i.e., pairwise) distinct visual stimuli, with 
responses on one stimulus rewarded with food 
and responses on the other producing a timeout 
period during which additional responses can-
not be made (Figure 3C). After reaching a pre-
determined criterion of discrimination (e.g., 
>85% correct choices), the stimulus-reward 
contingencies are reversed and the subject must 
inhibit perseverative responses to the previously 
rewarded stimulus and learn to respond to the 
alternate, previously unrewarded, stimulus 
(Figure 3D).
The capacity for this system to concurrently 
assess discrimination as well as reversal learn-
ing provides an excellent internal control, not 
only for learning and behavioral performance 
generally, but also because discrimination is 
impaired in some cases of schizophrenia. For 
example, discrimination and reversal learning 
Cognitive ﬂ  exibility in mice
Figure 3 | Touchscreen-based operant system for assaying 
discrimination and reversal learning in mice. 
Training and testing entails four stages. (A) To ﬁ rst teach the mouse 
to associate rewards with visual stimuli on the touchscreen, 
food pellets and stimuli are presented concomitantly. 
(B) Next, the mouse must respond to stimuli on the screen to obtain 
a reward (and also initiate new trials via a head-entry into the magazine). 
(C) During discrimination learning, two novel stimuli are presented on the 
screen, and the mouse must respond to one stimulus (to obtain reward) 
and not the other (to avoid non-reward and a timeout phase during 
which no new trials can be initiated). (D) In the ﬁ  nal stage, 
the stimulus-reward contingency is reversed, and the mouse must now 
respond to the previously unrewarded stimulus to obtain reward. 
Note: the left/right position of rewarded stimuli varies pseudorandomly 
across trials, and the type of rewarded stimulus is counterbalanced 
across mice.
Subchronic PCP “model” 
of schizophrenia
Based on the clinical observation 
that phencyclidine (PCP) and other 
NMDAR antagonists mimic symptoms 
of schizophrenia in healthy individuals, 
Jentsch and Roth (1999) developed a 
procedure involving repeated treatment 
of monkeys and rodents with PCP
 to produce cognitive deﬁ  cits and 
associated prefrontal neurochemical 
abnormalities.24 | May  2010 | Volume  4 | Issue  1  www.frontiersin.org
 contrast, the same treatment regimen that failed 
to affect discrimination or reversal was sufﬁ  cient 
to reduce social behavior – demonstrating that 
treatment was sufﬁ  cient to mimic some symp-
toms of schizophrenia.
While  Brigman et  al. (2009) was the ﬁ  rst 
study of the PCP model in a rodent touch-
screen-based procedure, the lack of impair-
ment may appear somewhat surprising, given 
PCP-induced deﬁ  cits have been found on other 
measures of reversal in rats and mice (summa-
rized in Table 1). However, similar to Brigman 
et al., negative effects on reversal have also been 
reported (including in studies in which there 
are clear PCP-induced deﬁ  cits in the EDS com-
ponent, e.g., Rodefer et al., 2005, 2008; Egerton 
et al., 2008). Direct comparisons between stud-
ies are further complicated by variations in treat-
ment regimen and methodology. For example, 
while Neill and colleagues (Abdul-Monim et al., 
2006, 2007) have demonstrated reversal impair-
ments in a light-cue based operant task in rats 
subjected to a PCP treatment and withdrawal 
procedure comparable to Brigman et al., their 
task required subjects to completely inhibit 
responses on some trials to obtain reward, 
which likely placed greater demands on inhibi-
tory control than the task used by Brigman et al. 
(in which a response was always available). This 
is likely a salient difference because subchronic 
PCP treatment impairs inhibitory control in rats 
and non-human primates (Jentsch et al., 1997b, 
2000; Jentsch and Taylor, 2001). Clearly, further 
work is needed to parse the most critical features 
of reversal assays that render them sensitive to 
subchronic PCP treatment.
research program to elucidate the role of gluta-
mate in cognitive and executive functions, we 
have studied the effects of null mutations in 
various components of the glutamate system on 
the touchscreen-based method (Brigman et al., 
2008; Karlsson et al., 2008; Wiedholz et al., 2008; 
Karlsson et al., 2009). To compliment and extend 
these studies, we (Brigman et al., 2009) investi-
gated a pharmacological model of glutamatergic 
dysfunction in schizophrenia – subchronic PCP 
treatment.
PCP and other NMDAR antagonists (e.g., 
ketamine) mimic positive and negative symp-
toms of schizophrenia in otherwise healthy indi-
viduals (Javitt and Zukin, 1991; Krystal et al., 
1994). Based upon this observation, Jentsch and 
colleagues subchronically treated monkeys and 
rats with PCP and found cognitive deﬁ  cits and 
associated prefrontal neurochemical abnormali-
ties (reviewed in Jentsch and Roth, 1999). The 
subchronic PCP model has since been quite 
widely employed as a rodent model for execu-
tive dysfunctions in schizophrenia.
In order to test the subchronic PCP model 
in the touchscreen-based assay, Brigman et al. 
(2009) treated C57BL/6J mice with 5  mg/kg 
PCP twice daily for 7 days and, after a 7-day 
withdrawal period, tested for discrimination 
and (in a separate group of mice) reversal in 
the touchscreen-based task. This treatment and 
withdrawal duration was based on previous 
work by Jentsch et al. (1997a). Results showed 
no signiﬁ   cant impairments in drug-treated 
mice in comparison to vehicle treated controls 
on either discrimination or reversal, as meas-
ured using a range of dependent variables. By 
Brigman et al.
Table 1 | Studies on the effects of acute and chronic PCP treatment on measures of cognitive ﬂ  exibility.
Species  Assay (stimulus modality)  PCP treatment regimen (dose)  Reference
Rat  Operant reversal (visual)  Acute (1.0–1.5 mg/kg)  Abdul-Monim et al. (2003)
Rat  Operant reversal (visual)  Acute (1.5–2.0 mg/kg)  Idris et al. (2005)
Rat  Operant reversal (visual)  Chronic, daily (2 mg/kg) × 7 days, +7 days w/d  Abdul-Monim et al. (2006)
Rat  Operant reversal (visual)  Chronic, daily (2 mg/kg) × 7 days, +7 days w/d  Abdul-Monim et al. (2007)
Mouse  Operant reversal (visual)  Chronic, twice daily (5 mg/kg) × 7 days, +7 days w/d  Brigman et al. (2009)
Rat  Spatial reversal (visual)  Chronic, twice daily (5 mg/kg) × 7 days, +7 days w/d  Jentsch and Taylor (2001)
Rat  IDS/EDS (tactile/olfactory)  Acute (2.58 mg/kg)  Egerton et al. (2005)
Rat  IDS/EDS (tactile/olfactory)  Repeated (10–20 mg/kg) on postnatal days P7 , 9, 11  Broberg et al. (2008)
Rat  IDS/EDS (tactile/olfactory)  Chronic, daily (2.6 mg/kg) × 5 days, +3 days w/d  Egerton et al. (2008)
Mouse  IDS/EDS (tactile/olfactory)  Chronic, daily (0.63–1.3 mg/kg) × 10 days  Laurent and Podhorna (2004)
Rat  IDS/EDS (tactile/olfactory)  Chronic, twice daily (5 mg/kg) × 7 days, +10 days w/d  Rodefer et al. (2005)
Rat  IDS/EDS (tactile/olfactory)  Chronic, twice daily (5 mg/kg) × 7 days, +10 days w/d  Rodefer et al. (2008)
Monkey  Detour reaching task  Chronic, twice daily (0.3 mg/kg) × 14 days, +7 days w/d  Jentsch et al. (1997a)
IDS/EDS, intra-dimensional/extra-dimensional set shifting; w/d, withdrawal period prior to testing.Frontiers in Neuroscience  May  2010 | Volume  4 | Issue  1 | 25
given the aforementioned clinical data hint-
ing that the range of executive deficits may 
increase in tandem with disease chronicity 
and severity. In this context, another inter-
esting course would be to parametrically 
vary dose and/or chronicity of treatment 
to ask whether more “intensive” treatment 
regimens produced significant reversal defi-
cits. Beyond the subchronic PCP model, the 
touchscreen-based system has great potential 
for evaluating mouse models of schizophrenia 
CONCLUDING REMARKS
The Brigman et al. data raise some interest-
ing questions for further studies examining 
the effects of subchronic PCP on reversal in 
the touchscreen system. For example, would 
increasing the difficulty of the reversal (e.g., 
by increasing the perceptual similarity of the 
visual stimuli), presenting distracters, or mak-
ing reinforcement probabilistic, increase the 
sensitivity of the assay to PCP treatment? Such 
task-dependent effects would be intriguing, 
Cognitive ﬂ  exibility in mice
Table 2 | Examples of studies of cognitive ﬂ  exibility in mutant mice.
Assay  Mutant  Reversal effect  Reference
IDS/EDS HdhCAC(150) knock-in  Impaired   Brooks et al. (2006)
IDS/EDS  Dopamine D2 receptor knockout  Impaired  De Steno and Schmauss (2009)
IDS/EDS  Dopamine D3 receptor knockout  Facilitated  Glickstein et al. (2005)
IDS/EDS  COMT-Val transgenic  None  Papaleo et al. (2008)
IDS/EDS  Tg2576 APP Swedish mutation  Impaired  Zhuo et al. (2007)
MWM  p25 fragment accumulation  Facilitated  Angelo et al. (2003)
MWM  Vesicular glutamate transporter deﬁ  cient  Impaired  Balschun et al. (2009)
MWM  N-terminal amidase deﬁ  cient  Facilitated  Balogh et al. (2001)
MWM Ins2C96Y Akita  None  Choeiri et al. (2005)
MWM  Rac3 knockout  Impaired  Corbetta et al. (2008)
MWM  TgCRND8 APP double mutant  Impaired  Chishti et al. (2001)
MWM  Synaptic vesicle protein (Rab3a) deﬁ  cient  Impaired  D’Adamo et al. (2004)
MWM NaSi-1 sulfate transporter deﬁ  cient  None  Dawson et al. (2005)
MWM PDE1B−/− DARPP32−/− double knockout  Impaired  Ehrman et al. (2006)
MWM  CREBcomp mutant  Impaired  Gass et al. (1998)
MWM  mGluR4 deﬁ  cient  Facilitated  Gerlai et al. (1998)
MWM  α3-GABAa deﬁ  cient  Trend for impaired  Fiorelli et al. (2008)
MWM  PS1 transgenic, L235P mutation  None  Huang et al. (2003)
MWM  β-amyloid precursor protein transgenic  Impaired  Koistinaho et al. (2001)
MWM  D-amino acid oxidase deﬁ  cient  Facilitated  Labrie et al. (2009)
MWM  Presenilin 1 knockout  Rescues APP transgenic  Saura et al. (2005)
MWM  Protein tyrosine phosphatase-alpha deﬁ  cient  None  Skelton et al. (2003)
MWM  Offspring of vasoactive intestinal peptide deﬁ  cient dams  Impaired  Stack et al. (2008)
MWM  Guanine nucleotide exchange factor (Ric-8) deﬁ  cient  Impaired  Tonissoo et al. (2006)
MWM  CB1 endocannabinoid receptor deﬁ  cient  Impaired  Varvel and Lichtman (2002)
MWM  GDNF receptor α2 deﬁ  cient  Impaired  Voikar et al. (2004)
Operant  Heterozygous Reln deﬁ  cient “Reeler Mouse”  Impaired  Brigman et al. (2006)
Operant  Heterozygous Reln deﬁ  cient “Reeler Mouse”  None  Krueger et al. (2006)
Olfactory  TgS and TgR acetylcholinesterase disruption  None  Kofman et al. (2007)
Olfactory  Dopamine D2 receptor knockout  Impaired  Kruzich et al. (2006)
Olfactory  Phenylalanine hydroxylase deﬁ  cient  Impaired  Zagreda et al. (1999)
Spatial  AMPA receptor subunit (GluRA) knockout  Impaired  Bannerman et al. (2003)
Spatial  Brain and spinal cord myelin deﬁ  cient  Impaired  Elias and Eleftheriou (1972)
Spatial  APP/PS1 transgenic  Age-related impairment  Filali and Lalonde (2009)
Spatial  Ts65Dn cholinergic deﬁ  cient Down’s model  Impaired  Granholm et al. (2000)
Spatial  DARPP-32 knockout  Impaired  Heyser et al. (2000)
Spatial  PEPCK bGH transgenic elevated growth hormone  Facilitated  Meliska et al. (1997)
Spatial  APP/PS1 transgenic Alzheimer’s model  None  O’Leary and Brown (2009)
Spatial  AMPA receptor subunit (GluRA) knockout  Impaired  Schmitt et al. (2004)
IDS/EDS, intra-dimensional/extra-dimensional shifting task; MWM, Morris water maze.26 | May  2010 | Volume  4 | Issue  1  www.frontiersin.org
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